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Background: All established disease-modifying drugs for multiple sclerosis require parenteral 
administration, which can cause difficulties for some patients, sometimes leading to suboptimal 
adherence. A new electronic autoinjection device has been designed to address these issues.
Methods: Patients with relapsing multiple sclerosis currently receiving subcutaneous or 
intramuscular interferon beta-1a, interferon beta-1b, or glatiramer acetate completed an online 
questionnaire (July 4–25, 2008) that surveyed current injection practices, experiences with 
current injection methods, and impressions and appeal of the new device.
Results: In total, 422 patients completed the survey, of whom 44% used autoinjectors, 43% 
prefilled syringes, and 13% syringes and vials; overall, 66% currently self-injected. Physical and 
psychological barriers to self-injection included difficulty with injections, needle phobia, and 
concerns over correct injection technique. Only 40% of respondents were “very satisfied” with 
their current injection method. The new electronic autoinjector was rated as “very appealing” 
by 65% of patients. The benefits of the new device included the ability to customize injection 
settings and to review dosing history.
Conclusion: New technologies may help patients overcome physical and psychological bar-
riers to self-injection. The combination of a reliable and flexible autoinjection device with 
dose-monitoring technology may improve communication between health care professionals 
and patients, and improve treatment adherence.
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Background
Multiple sclerosis is a chronic degenerative disease of the central nervous system, 
and is the most common disabling neurological condition affecting young adults.1,2 
Because multiple sclerosis is currently incurable, patients require long-term treatment 
that delays or stops the progression of irreversible disability. Currently, the first-line 
therapies for relapsing forms of multiple sclerosis are interferon (IFN) beta-1a 44 µg 
or 22 µg administered subcutaneously three times weekly (Rebif®, Merck Serono 
S.A., Geneva, Switzerland); IFN beta-1a 30 µg administered intramuscularly once 
weekly (Avonex®, Biogen Idec Inc, Cambridge, MA); IFN beta-1b 250 µg adminis-
tered subcutaneously every other day (Betaferon®/Betaseron®, Bayer Schering Pharma 
AG, Berlin, Germany; Extavia®, Novartis AG, Basel, Switzerland); and glatiramer 
acetate 20 mg administered subcutaneously daily (Copaxone®, Teva Pharmaceutical 
Industries Ltd, Petah Tikva, Israel). All these first-line disease-modifying drugs for 
multiple sclerosis require parenteral self-administration, by either subcutaneous or 
intramuscular injection.3Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Adherence to multiple sclerosis treatment is important to 
ensure optimal clinical outcomes.4,5 However, the debilitat-
ing nature of the disease itself, together with the need for 
long-term, frequent, parenteral drug administration, means 
that adherence is a challenge for many patients. A recent 
multicenter observational study of 2648 patients reported 
that 25% of 2566 patients for whom data were available (643 
patients) were nonadherent (defined as missing at least one 
disease-modifying drug injection over a four-week period).6 
Among these nonadherent patients, 32% reported injection-
related reasons for their nonadherence.
There are limited prospective data on factors that influ-
ence adherence to disease-modifying drugs.7 However, con-
tributing factors to nonadherence that have been identified 
include problems with injecting, perceived lack of efficacy, 
and adverse events.5,7,8 Patients who are required to self-inject 
often react with fear, avoidance, anxiety, or disgust, with 
some asking family members to administer the treatment 
to avoid self-injection.5 However, dependence on others 
for injection may also reduce treatment adherence.5 Other 
injection-related barriers to adherence include injection site 
reactions and injection pain.7 In an observational study that 
surveyed patients via online questionnaires, factors directly 
related to the injection of therapy accounted for 32% of the 
reasons given for missing injections, including “tired of 
shots”, “skin reactions”, and “pain at injection site”.7 Addi-
tionally, many patients with multiple sclerosis have reduced 
manual dexterity, which can make the correct self-injection 
procedure physically problematic.
In response to these potential problems with injecting, 
various injection technologies have been introduced, which 
are designed to improve convenience and the safety and reli-
ability of injections, and to reduce pain and anxiety.8 These 
technological developments include thinner needles, prefilled 
syringes for manual injection, and autoinjection devices 
(or “autoinjectors”). Autoinjectors automatically insert the 
needle and deliver a controlled dose, and are available for all 
first-line disease-modifying drugs used for multiple sclerosis 
with the exception of intramuscular IFN beta-1a, for which 
an injection device is available, but the injection process 
remains partially manual. Autoinjectors have been shown 
to provide a number of benefits, including a reduced risk of 
injection site reactions, reduced discomfort, and greater ease 
of use compared with manual syringe injections.9–11
A recent cross-sectional, questionnaire-based survey of 
3006 patients with multiple sclerosis examined patients’ 
reasons for using or for being reluctant to use an autoin-
jector for the subcutaneous administration of IFN beta or 
glatiramer acetate.12 The reasons most commonly cited by 
patients for using an autoinjector were “certainty that the 
injection was being carried out correctly” (47.1% of patients) 
and the ability to administer injections at sites on the body 
that were previously inaccessible (41.1%). A major reason 
for not using an injection device, cited by 34.4% of patients, 
was that patients wanted control of the injection, including 
control of the speed and depth of needle insertion, as well 
as the duration of the injection. The survey also found that 
treatment adherence was greater among patients who always 
used an autoinjector (79% stated that they never missed an 
injection) than in those who used a prefilled syringe (71% 
stated that they never missed an injection). However, over 
20% of patients who always used an autoinjector still reported 
that they sometimes missed an injection.
Adherence to treatment in multiple sclerosis thus remains 
suboptimal, indicating that patients may still have unmet 
needs. In the survey by Bayas et al,12 patients were also asked 
to identify the characteristics that an ideal autoinjector should 
have. The most frequently cited characteristics included the 
ability to carry out the injection simply and swiftly in just 
a few steps, drug release only with skin contact, preven-
tion of accidental activation, and the opportunity to adjust 
needle insertion speed, as well as injection depth, speed, and 
  duration. Advances in delivery technology towards this ideal 
profile may, therefore, offer greater patient convenience and 
increase adherence.8
A new electronic, multidose autoinjector (RebiSmart™, 
Merck Serono S.A., Geneva, Switzerland) has been devel-
oped for administering subcutaneous IFN beta-1a.13,14 This 
device offers a number of innovative features designed to 
improve the convenience and comfort of subcutaneous IFN 
beta-1a administration. Patients using this device have the 
facility to improve injection comfort by adjusting the needle 
insertion speed, needle depth, injection speed, and injection 
time (the time between the end of injection and needle retrac-
tion). In addition, interactive onscreen instructions, together 
with clear visual and audible signals, provide guidance for 
correct use. The device also features a dosing log that records 
the date, time, and dosage of every injection. This function 
may help patients to avoid missing doses, and thus potentially 
improve adherence.
Here we report the results of an online survey of patients 
diagnosed with relapsing multiple sclerosis and currently 
receiving treatment with subcutaneous IFN beta-1a, 
intramuscular IFN beta-1a, subcutaneous IFN beta-1b, or 
glatiramer acetate. The aims of the survey were to inves-
tigate patients’ injection practices in the normal clinical Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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setting, to   evaluate their experiences with current injection 
methods, and to assess their reactions to the new electronic 
autoinjector.
Methods
Eligible patients in Canada, France, Germany, Italy, Spain, 
and the US were recruited from an online panel of patients 
and completed an online, self-administered questionnaire 
during July 4–25, 2008. Patients were eligible if they were 
aged 18–65 years, had a diagnosis of relapsing multiple scle-
rosis or had experienced a demyelinating event   suggestive of 
multiple sclerosis, were currently receiving IFN beta or 
glatiramer acetate, had been injecting treatment for at least 
two months prior to participating in the survey, and were not 
affiliated with any medical marketing, market research, or 
pharmaceutical company.
Patients were shown a series of slides describing the new 
electronic, multidose autoinjector, its key features, and the 
injection procedure, including insertion and removal of the 
drug cartridge and needle. The questionnaire was designed 
to collect information on current injection practices, patients’ 
attitudes to and experience with current treatment, and 
impressions and appeal of the new electronic autoinjector 
(Table 1). The questionnaire consisted mainly of multiple-
choice questions and took approximately 30 minutes to 
complete. Three of the questions asked patients to indicate 
their attitudes on a scale of 0–10, ranging from “not at all” 
(score of 0) to “very comfortable/satisfied/appealing” (score 
of 10). For question 9 (satisfaction with the patient’s cur-
rent injection method), a score of 0–2 was categorized as 
“unsatisfied”, 3–7 as “moderately satisfied”, and 8–10 as 
“very satisfied”. The responses to questions 1 and 10 were 
also categorized using these score ranges.
Results
Demographics, patient clinical 
characteristics, and current therapy
In total, 422 patients completed the survey in Canada (n = 35, 
8%), France (n = 35, 8%), Spain (n = 45, 11%), Germany 
(n = 50, 12%), Italy (n = 47, 11%), and the US (n = 210, 50%). 
Patient demographic and clinical characteristics are presented 
in Table 2. Respondents had been receiving injected therapy 
for a mean of 4.2 years. The most common current therapy 
was subcutaneous IFN beta-1a, which was being received 
by 189 respondents (45%). A further 85 respondents (20%) 
were currently receiving treatment with intramuscular IFN 
beta-1a, 60 (14%) with subcutaneous IFN beta-1b, and 88 
(21%) with glatiramer acetate.
Current injection habits
Overall, a similar proportion of respondents used prefilled 
syringes (43%) and autoinjectors (44%), while a smaller 
percentage (13%) used syringes and vials (Figure 1). How-
ever, when analyzed by current drug used, the percentage of 
respondents using autoinjection devices was smaller among 
patients taking intramuscular IFN beta-1a (15%) than among 
patients taking subcutaneous IFN beta-1a (54%), IFN beta-1b 
(42%), or glatiramer acetate (51%, Figure 1).
Approximately two-thirds (66%) of respondents self-
injected, while 19% had someone else administer the   injection. 
The remaining 15% of patients sometimes self-injected and 
sometimes had someone else inject their medication. Rates of 
self-injection were similar among patients treated with subcu-
taneous IFN beta-1a (71%), IFN beta-1b (65%), or glatiramer 
acetate (70%), but lower among those receiving intramuscular 
IFN beta-1a (51%). Patients reported a number of physical 
and psychological reasons for not currently self-administering 
injections (Figure 2). The most common reason was physical 
difficulty with injecting (57% of respondents), whereas pain 
on injection was cited by only 10% of respondents. The most 
common psychological reasons for not self-injecting included 
dislike of looking at needles (39%), dislike of the thought of 
injecting (37%), and a lack of confidence in their ability to 
inject correctly (32%). When patients were asked to rate their 
satisfaction with their current injection method on a scale of 
0–10 (0 = not at all satisfied, 10 = very satisfied), the mean 
score was 6.7 (median 7.0, range 0–10). Overall, 40% of 
respondents were “very satisfied” (score of 8–10) with their 
current injection method (Table 3), with a lower percentage 
among users of vials and syringes (23%) than among users 
of prefilled syringes (39%) or autoinjectors (46%).
Attitudes to technology
Most respondents were very comfortable in general with new 
technologies. On a scale of 0–10 (0 = not at all comfortable, 
10 = very comfortable), the mean score was 8.0 (median 8.0, 
range 0–10), and 69% of patients scored between 8 and 10; 
29% were somewhat comfortable (score of 3–7), and only 2% 
were uncomfortable (score of 0–2). Approximately one-third 
(35%) of respondents described themselves as early adopters 
of new technologies, while 57% described themselves as 
cautious adopters, and only 8% as late adopters.
reactions to the new electronic 
autoinjection device
When patients were asked how appealing the new electronic 
autoinjection device was compared with their current method Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 survey questionnaire
Question Response
1.   Thinking generally about new technologies, how comfortable  
would you say you were with technical electronic instruments  
such as computers and mobile phones?
scale of 0 (not at all) to 10 (very comfortable)
2.   Which of the following best describes your approach to new 
technologies?
1.   I am always one of the first to try new technologies (early adopter) 
2.   i tend to wait until others have tried and tested a new technology before 
using it myself (cautious adopter) 
3.   i am usually amongst the last to start using a new technology (late 
adopter)
3.   Which of the following types of Ms do you currently have? 1. relapsing–remitting 
2. secondary progressive 
3. Clinically isolated syndrome 
4. Don’t know
4. How long ago were you first diagnosed with MS? Length of time
5. For how long have you been injecting this Ms treatment? Length of time
6.   Which of the following do you currently use to inject  
your Ms treatment?
1. A syringe that requires you to fill from a vial 
2. A prefilled syringe 
3. Autoinjection device 
7.   Do you currently inject yourself or do you have someone  
else inject for you?
1. i inject myself 
2. someone else injects me 
3. Both
8.   For which of the following reasons do you not currently  
inject your treatment yourself?a
1. I find it physically difficult to inject myself 
2. it hurts to inject myself 
3. i don’t like looking at needles 
4. i don’t like the thought of having to inject myself 
5. i don’t trust i will inject myself correctly 
6. I find the syringe/injection device unsafe 
7. Otherb
9.   How satisfied would you say you were with the injection  
method you currently use for administering treatment?
Scale of 0 (not at all) to 10 (very satisfied)
Questions after viewing presentation on the new electronic, multidose autoinjector
10.   how appealing is this new injection device compared  
with your current method?
scale of 0 (not at all) to 10 (very appealing)
11.   Which of the following do you feel are the key benefits  
of this new electronic device that would encourage you  
to ask your nurse or doctor about it?a
1. Ability to tailor injection settings to individual patient needs 
2. reliable monitoring of regular dosing 
3. Could allow for easier access to various injection sites 
4. simple uncomplicated procedure 
5. hidden needle 
6.   Sounds, lights, and onscreen prompts ensure correct and confident delivery 
of dose 
7. Looks easy to grip and handle the device 
8. Compact 
9. Ability to download dosing information to computer 
10. Looks less like a medical device 
11. Otherb 
12. There are no benefits
12.   Which of the following do you feel are the key drawbacks  
of this new electronic device that would discourage you  
from asking your nurse or doctor about it?a
1. The device may malfunction 
2. requires a screwdriver to change batteries 
3. Too many steps to prepare the injection 
4. Too many steps involved in actually injecting 
5. Could be too large to handle comfortably 
6. Information screen could be difficult to read 
7. Patient is less in control of the injection 
8. Dosing log implies a lack of physician’s trust 
9. Otherb 
10. There are no drawbacks to using this device
Notes: aRespondents could give more than one reason, benefit, or drawback; bother benefits or drawbacks cited by patients were recorded. 
Abbreviation: Ms, multiple sclerosis.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Patient demographic and clinical characteristics
Characteristics
Age, years
  Mean (sD) 43 (10.7)
  Median (range) 44 (18–64)
Age range, n (%)
  18–30 years 72 (17)
  31–40 years 122 (29)
  41–50 years 126 (30)
  51–65 years 102 (24)
sex, n (%)
  Male 127 (30)
  Female 295 (70)
Clinical form of Ms, n (%)
  Clinically isolated syndrome 40 (9)
  relapsing–remitting 300 (71)
  secondary progressive 57 (14)
  Unknown 25 (6)
Time since diagnosis of Ms, years
  Mean (sD) 8.4 (6.7)
  Median (range) 6 (1–41)
Length of time injecting Ms therapies, years
  Mean (sD) 4.2 (3.6)
  Median (range) 3.2 (0.2–36.5)
Abbreviations: Ms, multiple sclerosis; sD, standard deviation.
on a scale of 0–10 (0 = not at all appealing, 10 = very appeal-
ing), the overall mean score was 7.7 (median 8.0, range 
0–10). Approximately two-thirds (65%) of patients found the 
new device “very appealing” (score of 8–10), with a higher 
proportion among current users of subcutaneous IFN beta-1a 
(73%) and IFN beta-1b (70%) than among users of intra-
muscular IFN beta-1a (54%) and glatiramer acetate (56%) 
favoring the new device. Overall, the new device was rated 
as moderately appealing (score of 3–7) by 30% of patients, 
and not at all appealing (score of 0–2) by 5%.
Questions 11 and 12 presented the patients with lists of 
several potential benefits and drawbacks of the new device. 
Overall, 96% of respondents identified a benefit that would 
encourage them to ask their nurse or doctor about the new 
device. The most appealing benefits were the ability to tailor 
injection settings (such as speed of injection and depth of 
needle insertion) to individual needs (cited by 39% of respon-
dents), and the dosing log that allows reliable monitoring of 
regular dosing (cited by 38%, Figure 3). Overall, 23% of 
respondents considered that the device had no drawbacks. The 
most frequently stated drawback was fear that the device might 
malfunction, which was cited by 37% of respondents.
Discussion
This survey of patients with relapsing multiple sclerosis indi-
cates that patterns of self-injection practice and satisfaction 
with current injection methods are broadly similar across the 
two groups in the US and the European Union/Canada. Auto-
injection devices and prefilled syringes were used by most 
respondents, but the use of autoinjectors was considerably 
less common among patients treated with intramuscular IFN 
beta-1a than in patients receiving other disease-modifying 
drugs, which reflects the lack of a fully automated injection 
device for use with this treatment.
A third of respondents reported that they relied on others 
(at least part of the time) to administer injections. The per-
centage of patients who self-injected among those receiving 
medications for which an autoinjector is available (ie, sub-
cutaneous IFN beta-1a, IFN beta-1b, and glatiramer acetate) 
was 65%–71%. In contrast, the percentage of patients receiv-
ing intramuscular IFN beta-1a who self-injected was 51%. 
While it should be noted that the routes of administration are 
different in these two cases and there may be differences in 
clinical characteristics between these populations, these data 
could suggest that self-injection might be more acceptable 
if an autoinjector is available than if the injection must be 
performed manually.
The percentage of patients who were either unsatisfied 
or only moderately satisfied with their current method of 
administration ranged from 54% among patients using an 
autoinjection device to 60% among patients using a prefilled 
syringe and 78% among those using vials and syringes. These 
findings indicate that even among patients already using an 
autoinjection device, there is scope for improvements in 
autoinjector design that may increase patient satisfaction 
with their injection method. It should be noted that 9% of 
subcutaneous IFN beta-1a patients reported using a syringe 
and vial although this drug was not available in such a deliv-
ery format at the time of the survey.
Results from this multinational survey indicate that 
patients reacted favorably to the new electronic autoinjection 
device. The design improvements that were found to be most 
appealing to patients were the dosing log and the ability to 
tailor injection settings to suit individual needs. The new 
electronic autoinjector appraised in this survey has also been 
evaluated in another study, which assessed ease of use and 
suitability in 106 patients with multiple sclerosis who had 
the opportunity to use the device.13 Most patients considered 
the device suitable for self-injection, with 95% of patients 
rating it as “easy” or “very easy” to use, and over 80% of 
patients rating individual features, such as dose history, 
confirmation of end of injection, audible and visual signals, 
and display of last injection time and date, as “useful” or 
“very useful”. Additional international user trials will further Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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validate the new device in patients with relapsing-remitting 
multiple sclerosis.14
It should be acknowledged that patient characteristics 
outside the scope of this analysis, such as patient age and 
length of time previously injecting therapy, could influence 
patient responses to these questions. The online format of this 
survey may have selected for patients who are more comfort-
able with technology. This survey confirms the findings of 
previous studies that have found that barriers to self-injection 
include both physical factors, such as injection pain, and 
psychological factors, including anxiety about the use of 
needles.5,8 However, this survey also found that over two-
thirds of respondents were “very comfortable” with new tech-
nologies. These results suggest that new technologies such as 
those incorporated in the new electronic autoinjection device 
could potentially help large numbers of patients to, at least 
partially, overcome some of the physical and psychological 
barriers to self-injection. In particular, the ability to adjust 
speed and depth of needle insertion and injection speed and 
time may allow patient comfort to be maximized. Conceal-
ment of the needle may also reduce needle-related anxiety. 
Evidence from the field of diabetes suggests that use of an 
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Figure 3 Benefits of the new autoinjection device most commonly cited by patients. Respondents could cite more than one benefit (values total more than 100%).
Table 3 satisfaction with current injection method
Method of injection Satisfaction score
Mean Median Range Category (percentage of patients)
0–2 
“unsatisfied”
3–7 
“moderately satisfied”
8–10 
“very satisfied”
All patients  
(n = 422)
6.7 7.0 0–10 6 54 40
Vial and syringe  
(n = 53)
5.9 6.0 1–10 8 69 23
Prefilled syringe  
(n = 183)
6.7 7.0 0–10 6 55 39
Autoinjection device  
(n = 186)
6.9 7.0 0–10 5 49 46Patient Preference and Adherence
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automatic injection device that conceals the needle   during 
the entire injection process is associated with significantly 
reduced pain perception.15 Furthermore, by providing reas-
surance regarding correct injection technique and improv-
ing the comfort of the injection, this new autoinjector may 
improve adherence. Importantly, the dosing log incorporated 
into the device provides an objective means by which to 
assess adherence to subcutaneous IFN beta-1a treatment and 
may facilitate discussion between patients and health care 
professionals, which may, in turn, improve adherence and 
treatment decision-making.
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